As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

HYDERABAD: IT and Industries Minister D Sridhar Babu on Thursday announced that the Congress government has secured ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor. Both drugs have ...

Analysts had predicted that the new drug class would be priced at around $10,000 a year, so the premium being sought by Amgen and Sanofi in the US will increase calls for measures to pare down the ...

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...